Clinical Trials Logo

Clinical Trial Summary

Phase Ib, single centre, double-blind, double-dummy placebo-controlled, randomised, stepwise dose escalated, vaccine trial to assess the safety and immunogenicity of the candidate ChAdOx1 Chik and ChAdOx1 Zika vaccines, given as a standalone vaccines or in co-administration. Healthy volunteers aged 18-50 years old, residents of the metropolitan area of Monterrey (Mexico), will be recruited as participants


Clinical Trial Description

This trial consists of 4 intervention arms according to the vaccination product: 1) ChAdOx1 Chik, 2) ChAdOx1 Zika, 3) ChAdOx1 Chik and ChAdOx1 Zika as contralateral co-administration, and 4) placebo. There will be a total of 120 participants divided in ten study groups with 12 participants per group (Table 5.1). Groups 1 to 3 will receive ChAdOx1 Chik + placebo administered contralaterally, Groups 4 to 6 will receive ChAdOx1 Zika + placebo administered contralaterally, and Groups 7 to 9 will receive both ChAdOx1 Chik and ChAdOx1 Zika administered contralaterally. Group 10 will receive placebo in both arms. Enrolment into this study will be implemented in a step-wise dose escalation manner. Participants will be first recruited into the vaccination groups at the lowest dose (Groups 1, 4 and 7). It is only after completion of these low dose groups and upon satisfactory interim clinical safety reviews that participants will be enrolled into the mid dose groups (Groups 2, 5 and 8). Participants in the high dose groups (Groups 3, 6 and 9) will be enrolled last, after completion and interim clinical safety reviews from the mid dose groups. Participants allocated to the Placebo group (Group 10) will be evenly distributed across the dose escalation model. Randomisation procedures will be implemented accordingly, at a ratio of 3:3:3:1 for each of the four intervention arms. The study involves a total of 9 visits (screening inclusive) and follow up will be undertaken for 6 months after vaccination day Innovate UK (project number 971557) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04440774
Study type Interventional
Source University of Oxford
Contact
Status Completed
Phase Phase 1
Start date October 23, 2020
Completion date February 18, 2022

See also
  Status Clinical Trial Phase
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT05153018 - Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu N/A
Active, not recruiting NCT04343521 - Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases Phase 3
Completed NCT03992872 - Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) Phase 2
Completed NCT03382964 - Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Phase 1
Completed NCT02831699 - The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
Recruiting NCT01099852 - Cohort of Patients Infected by an Arbovirus
Completed NCT06257810 - Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa Phase 4
Suspended NCT05218304 - Baromètre Santé Adulte 2021-2022 N/A
Recruiting NCT04615364 - Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Completed NCT04650399 - A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents Phase 3
Not yet recruiting NCT04672577 - Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
Completed NCT04434846 - Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
Recruiting NCT04838574 - Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Recruiting NCT04619823 - Virological and Immunological Determinants of Arbovirus Infection in New Caledonia N/A
Completed NCT03101111 - Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area Phase 2
Completed NCT02463968 - Chikungunya Arthritis in the Americas N/A
Active, not recruiting NCT04566484 - Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia Phase 2/Phase 3
Completed NCT04603131 - Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine Phase 1